Skip Nav Destination
Issues
1 January 2014
-
Cover Image
Cover Image
The cover shows immunofluorescent labeling of the blood-brain barrier marker GLUT-1 (red) in cultured human brain microvascular endothelial cells. Nuclei (blue) were stained with DAPI. For details, see the article by Malin and colleagues on page 56 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Perspectives in Drug Approval
Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary
Paul G. Kluetz; William Pierce; V. Ellen Maher; Hui Zhang; Shenghui Tang; Pengfei Song; Qi Liu; Martin T. Haber; Eldon E. Leutzinger; Ali Al-Hakim; Wei Chen; Todd Palmby; Elleni Alebachew; Rajeshwari Sridhara; Amna Ibrahim; Robert Justice; Richard Pazdur
CCR Drug Updates
Molecular Pathways
Review
Human Cancer Biology
αB-Crystallin: A Novel Regulator of Breast Cancer Metastasis to the Brain
Dmitry Malin; Elena Strekalova; Vladimir Petrovic; Allison M. Deal; Abraham Al Ahmad; Barbara Adamo; C. Ryan Miller; Andrey Ugolkov; Chad Livasy; Karen Fritchie; Erika Hamilton; Kimberly Blackwell; Joseph Geradts; Matt Ewend; Lisa Carey; Eric V. Shusta; Carey K. Anders; Vincent L. Cryns
Author Choice
A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma
Jeffrey S. Ross; Kai Wang; Laurie M. Gay; Rami N. Al-Rohil; Tipu Nazeer; Christine E. Sheehan; Timothy A. Jennings; Geoff A. Otto; Amy Donahue; Jie He; Gary Palmer; Siraj Ali; Michelle Nahas; Geneva Young; Elaine LaBrecque; Garrett Frampton; Rachel Erlich; John A. Curran; Kristina Brennan; Sean R. Downing; Roman Yelensky; Doron Lipson; Matthew Hawryluk; Vincent A. Miller; Philip J. Stephens
Cancer Therapy: Preclinical
Author Choice
Gambogic Acid Induces Apoptosis in Imatinib-Resistant Chronic Myeloid Leukemia Cells via Inducing Proteasome Inhibition and Caspase-Dependent Bcr-Abl Downregulation
Xianping Shi; Xin Chen; Xiaofen Li; Xiaoying Lan; Chong Zhao; Shouting Liu; Hongbiao Huang; Ningning Liu; Siyan Liao; Wenbin Song; Ping Zhou; Shunqing Wang; Li Xu; Xuejun Wang; Q. Ping Dou; Jinbao Liu
AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer
Philip D. Dunne; Darragh G. McArt; Jaine K. Blayney; Murugan Kalimutho; Samanda Greer; Tingting Wang; Supriya Srivastava; Chee Wee Ong; Ken Arthur; Maurice Loughrey; Keara Redmond; Daniel B. Longley; Manuel Salto-Tellez; Patrick G. Johnston; Sandra Van Schaeybroeck
Direct Inhibition of Retinoblastoma Phosphorylation by Nimbolide Causes Cell-Cycle Arrest and Suppresses Glioblastoma Growth
Swagata Karkare; Rishi Raj Chhipa; Jane Anderson; Xiaona Liu; Heather Henry; Anjelika Gasilina; Nicholas Nassar; Jayeeta Roychoudhury; Jason P Clark; Ashish Kumar; Giovanni M. Pauletti; Pradip K. Ghosh; Biplab Dasgupta
Cancer Therapy: Clinical
A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Vincent Ribrag; Jehan Dupuis; Herve Tilly; Franck Morschhauser; Fabrice Laine; Roch Houot; Corinne Haioun; Christiane Copie; Andrea Varga; John Lambert; Laurence Hatteville; Samira Ziti-Ljajic; Anne Caron; Sandrine Payrard; Bertrand Coiffier
Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase
Trine Zeeberg Iversen; Lotte Engell-Noerregaard; Eva Ellebaek; Rikke Andersen; Stine Kiaer Larsen; Jon Bjoern; Claus Zeyher; Cécile Gouttefangeas; Birthe Moerk Thomsen; Bente Holm; Per thor Straten; Anders Mellemgaard; Mads Hald Andersen; Inge Marie Svane
Author Choice
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
Geoffrey I. Shapiro; Jordi Rodon; Cynthia Bedell; Eunice L. Kwak; Jose Baselga; Irene Braña; Shuchi S. Pandya; Christian Scheffold; A. Douglas Laird; Linh T. Nguyen; Yi Xu; Coumaran Egile; Gerald Edelman
Author Choice
Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials
Charles Ferté; Marianna Fernandez; Antoine Hollebecque; Serge Koscielny; Antonin Levy; Christophe Massard; Rastislav Balheda; Brian Bot; Carlos Gomez-Roca; Clarisse Dromain; Samy Ammari; Jean-Charles Soria
Predictive Biomarkers and Personalized Medicine
Author Choice
Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients
Justin Guinney; Charles Ferté; Jonathan Dry; Robert McEwen; Gilles Manceau; KJ Kao; Kai-Ming Chang; Claus Bendtsen; Kevin Hudson; Erich Huang; Brian Dougherty; Michel Ducreux; Jean-Charles Soria; Stephen Friend; Jonathan Derry; Pierre Laurent-Puig
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds